Compare Standard Lithium Ltd (SLI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Standard Lithium Ltd trades at $1.62 (market cap $409.74M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 312.8× Standard Lithium Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Standard Lithium Ltd for 23 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SLI | VRTX | |
|---|---|---|
Market Cap | $409.74M | $128.16B |
Volume | 1,266,140 | 806,603 |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $557.96 |
52-Week Low | $1.61 | $407.37 |
Typical Hold Time | 23 Days | 120 Days |
Enterprise Value | $272.66M | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $1.65, down 4.62% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported no revenue in 2025 and negative net income of -$48.40M, though recent quarters show improving EPS trends with two consecutive beats. Key developments include progress toward a final investment decision for the South West Arkansas lithium project by end-2026 and new customer offtake agreements.
The stock presents high-risk, high-reward potential with 100% analyst buy ratings and a $3.83 consensus price target offering 132% upside. However, significant execution risks remain as the company transitions to commercial production, with negative cash flow from operations and substantial capital requirements ahead.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
